NovoCure Limited
Stock Forecast, Prediction & Price Target
NovoCure Limited (NVCR) stock Price Target by analysts
$30
Potential upside: 148.77%
NovoCure Limited price prediction
What is NovoCure Limited stock analysts` prediction?
NovoCure Limited stock forecast: Based on 2 Wall Street analysts` predicted price targets for NovoCure Limited in the last 3 months, the avarage price target is $30, with a high forecast of $NaN. The average price target represents a 148.77% change from the last price of $12.06.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
NovoCure Limited stock Price Target by analysts
Full breakdown of analysts given NovoCure Limited price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Vijay Kumar Evercore ISI | 0% 0/2 | 9 months ago | $30 148.77% upside | $26.43 | StreetInsider | Previous targets (1) |
Emily Bodnar H.C. Wainwright | 0% 0/5 | 11 months ago | $30 148.77% upside | $17.78 | StreetInsider | Previous targets (4) |
Emily Bodnar H.C. Wainwright | 0% 0/5 | about 1 year ago | $24 99.02% upside | $18.26 | StreetInsider | Previous targets (4) |
Emily Bodnar H.C. Wainwright | 0% 0/5 | over 1 year ago | $22 82.43% upside | $14.19 | StreetInsider | Previous targets (4) |
Vijay Kumar Evercore ISI | 0% 0/2 | over 1 year ago | $14.5 20.24% upside | $14.78 | StreetInsider | Previous targets (1) |
Jason Bednar Piper Sandler | 0% 0/1 | over 1 year ago | $28 132.19% upside | $14.88 | StreetInsider | Previous targets (0) |
Larry Biegelsen Wells Fargo | 0% 0/1 | over 1 year ago | $42 248.28% upside | $14.39 | StreetInsider | Previous targets (0) |
Unknown H.C. Wainwright | N/A | over 1 year ago | $24 99.02% upside | $14.64 | StreetInsider | N/A |
Unknown J.P. Morgan | N/A | over 2 years ago | $99 720.96% upside | $109.04 | Benzinga | N/A |
Unknown Wells Fargo | N/A | over 2 years ago | $107 787.30% upside | $118.81 | Benzinga | N/A |
Emily Bodnar H.C. Wainwright | 0% 0/5 | over 2 years ago | $140 1060.95% upside | $107.44 | TheFly | Previous targets (4) |
Unknown Wells Fargo | N/A | almost 3 years ago | $89 638.03% upside | $70.06 | Benzinga | N/A |
Emily Bodnar H.C. Wainwright | 0% 0/5 | over 3 years ago | $115 853.64% upside | $65.24 | TheFly | Previous targets (4) |
Jason Wittes Loop Capital Markets | 0% 0/1 | over 3 years ago | $200 1558.51% upside | $75.3 | Pulse 2.0 | Previous targets (0) |
NovoCure Limited Financial Estimates
NovoCure Limited Revenue Estimates
NovoCure Limited EBITDA Estimates
NovoCure Limited Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $535.03M N/A | $537.84M 0.52% | $509.33M -5.29% | Avg: $592.09M Low: $576.36M High: $611.16M avg. 16.24% | Avg: $657.80M Low: $642.80M High: $675.68M avg. 11.09% | Avg: $748.05M Low: $730.98M High: $768.38M avg. 13.71% | Avg: $831.8M Low: $812.82M High: $854.41M avg. 11.19% |
Net Income
% change YoY
| $-58.35M N/A | $-92.53M -58.58% | $-207.04M -123.74% | Avg: $-187.57M Low: $-215.97M High: $-151.07M avg. 9.40% | Avg: $-179.13M Low: $-221.29M High: $-140.12M avg. 4.49% | Avg: $-140.43M Low: $-145.39M High: $-136.27M avg. 21.60% | Avg: $-109.58M Low: $-113.45M High: $-106.33M avg. 21.96% |
EBITDA
% change YoY
| $-44.33M N/A | $-89.52M -101.93% | $-175.86M -96.44% | Avg: $-63.62M Low: $-65.66M High: $-61.93M avg. 63.82% | Avg: $-70.68M Low: $-72.60M High: $-69.06M avg. -11.09% | Avg: $-80.37M Low: $-82.56M High: $-78.54M avg. -13.71% | Avg: $-89.37M Low: $-91.80M High: $-87.33M avg. -11.19% |
EPS
% change YoY
| -$0.56 N/A | -$0.88 -57.14% | -$1.95 -121.59% | Avg: -$1.71 Low: -$2.03 High: -$1.42 avg. 12.30% | Avg: -$1.64 Low: -$2.08 High: -$1.32 avg. 4.31% | Avg: -$1.32 Low: -$1.37 High: -$1.28 avg. 19.32% | Avg: -$1.03 Low: -$1.07 High: -$1 avg. 21.96% |
Operating Expenses
% change YoY
| $464.48M N/A | $512.49M 10.33% | $613.92M 19.79% | Avg: $332.82M Low: $323.98M High: $343.54M avg. -45.78% | Avg: $369.76M Low: $361.32M High: $379.81M avg. 11.09% | Avg: $420.48M Low: $410.89M High: $431.92M avg. 13.71% | Avg: $467.56M Low: $456.90M High: $480.27M avg. 11.19% |
FAQ
What is NovoCure Limited stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 14.36% in 2025-2028.
We have gathered data from 6 analysts. Their low estimate is -215.97M, average is -187.57M and high is -151.07M.
What is NovoCure Limited stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 13.06% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $576.36M, average is $592.09M and high is $611.16M.
What is NovoCure Limited stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 14.47% in 2025-2028.
We have gathered data from 6 analysts. Their low earnings per share estimate is -$2.03, average is -$1.71 and high is $-1.42.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering NovoCure Limited stock. The most successful analyst is Vijay Kumar.